Developer docs
API playgroundTry for free, no card

Search company profiles

Synklino

Full company profile

uuid0002jr1

Namestring
Synklino
Legal namestring
Synklino A/S
Websiteurl
synklino.com
Company typeenum
Private
Founded yearint
2017
Descriptiontext

Synklino A/S is a Danish clinical-stage biotechnology company founded in July 2017 as a spinout from the University of Copenhagen and the Technical University of Denmark, headquartered at Frederiksborggade 1, Copenhagen K. The company is developing a single lead product, SYN002, a first-in-class therapeutic fusion protein (immunotoxin) designed to eliminate cytomegalovirus (CMV) infection in donor kidneys prior to transplantation. SYN002 targets US28, a CMV-encoded membrane receptor exclusively expressed on virus-infected cells during both lytic and latent phases, and is administered ex vivo during normothermic machine perfusion, treating the donor organ directly without exposing the transplant recipient to systemic therapy.

SYN002 addresses a clear unmet need: approximately 30% of kidney transplant recipients receiving CMV-positive donor organs still experience CMV reactivation despite standard antiviral prophylaxis, leading to increased morbidity, mortality, organ rejection, and a roughly 50% rise in transplant-related costs. Preclinical data published in the American Journal of Transplantation demonstrated greater than 90% reduction in CMV reactivation from latency in treated human donor kidneys. Synklino retains broad intellectual property rights to SYN002 and its ex vivo use in organ perfusion, built on a decade of academic research from its founding universities. The company initiated first-in-human Phase 1 clinical trials in 2026, with the first patient dosed in May 2026 at the Ajmera Transplant Centre, University Health Network Toronto, under Principal Investigator Prof. Atul Humar.

The business model is licensing- and partnership-driven: Synklino intends to develop SYN002 through proof-of-concept and then partner with established pharmaceutical companies for late-stage development and global commercialization, generating revenue from upfront payments, development milestones, and royalties. The company has raised approximately EUR 43.8 million in total across a 2019 BioInnovation Institute grant (DKK 10m), a 2020 seed round (Eir Ventures and Vaekstfonden), a heavily oversubscribed 2021 financing round (DKK 106m/EUR 14m), and a 2022 Series A of EUR 29.8m led by PKA pension fund with Vaekstfonden and Eir Ventures. Ownership includes approximately 70 private shareholders alongside institutional investors. The company is privately held, pre-revenue, and has 11–50 employees.

Short descriptiontext

Synklino A/S is a Danish clinical-stage biotechnology company developing SYN002, a first-in-class ex vivo therapeutic fusion protein that eliminates cytomegalovirus from donor kidneys during machine perfusion, targeting latent and active CMV infection in kidney transplant recipients.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersCopenhagen, Denmark
HQ citystring
Copenhagen
HQ countrystring
Denmark
HQ regionstring
Europe
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
cytomegalovirus therapeutics, kidney transplant drugs, ex vivo organ perfusion, therapeutic fusion proteins, antiviral immunotoxins
Industry2 codes
PRIMARYHLAAAAAD
Fusion Proteins & Fc-Engineered Biologics
Healthcare & Life Sciences/Biotechnology & Biologics/Therapeutic Biologics (mAbs, recombinant proteins, cytokines)
SECONDARYHLAAAAAJ
Engineered Protein Therapeutics (de novo/AI-designed proteins, novel scaffolds)
Healthcare & Life Sciences/Biotechnology & Biologics/Therapeutic Biologics (mAbs, recombinant proteins, cytokines)
NAICS code1 code
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
SIC code1 code
  • In Vitro & In Vivo Diagnostic Substances2835
Product category
Transplant Therapeutics
Social media profiles1 record
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model1 record
1Pharmaceutical Licensing/Partnership
TypeLicensing Royalties
Description

As a clinical-stage biotech, Synklino plans to develop SYN002 through proof-of-concept, after which they expect to partner with established pharma companies for late-stage development and commercialisation. Revenue will come from licensing deals, milestone payments, and royalties from commercial partners.

synklino.com
Marketing channels4 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components4 values
Technology or R&D, Personnel, Operations, Marketing or Sales
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

Synklino develops SYN002, a first-in-class therapeutic fusion protein (immunotoxin) that targets the CMV-encoded US28 membrane receptor to eliminate both active and latent cytomegalovirus-infected cells in donor kidneys. The drug is administered ex vivo during normothermic machine perfusion of the donor organ prior to transplantation, treating the organ directly so the transplant recipient is not exposed to systemic antiviral therapy. The company is currently advancing SYN002 through a Phase 1 clinical trial at University Health Network Toronto.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 4 values shown
  • >90% reduction in CMV reactivation from latency in human kidneys treated ex vivo
+3 more records
Product overview1 text field

Synklino is a Danish clinical-stage biotechnology company developing a single lead product, SYN002, a first-in-class ex vivo therapy for preventing cytomegalovirus (CMV) reactivation in kidney transplant recipients. SYN002 is a therapeutic fusion protein administered during ex vivo organ perfusion (machine perfusion) prior to transplantation, enabling direct treatment of the donor organ without systemic exposure to the recipient. The company is currently advancing SYN002 through Phase 1 clinical development and has no additional commercial products or services.

Product and service1 record
1SYN002
CategoryTransplant Therapeutics - Antiviral Biologic
Description

First-in-class therapeutic fusion protein (immunotoxin) that targets the CMV-encoded US28 membrane receptor on infected cells to eliminate both active (lytic) and latent cytomegalovirus from donor kidneys. Administered ex vivo during normothermic machine perfusion of the donor organ prior to transplantation, treating the donor organ directly so the transplant recipient is not exposed to systemic antiviral therapy. Intended for kidney transplant centers and their CMV-positive donor kidney recipients.

Scale indicator6 records

Each record includes

Type, Value, Description, Source

Partnership4 partners
Strategic tierCoreTypeStrategic or Co-development Partner
Description

Ajmera Transplant Centre at UHN is conducting the Phase 1 clinical trial of SYN002. One of the world's leading transplant centers, performing more than 600 solid organ transplants each year. Study led by Professor Atul Humar, internationally recognized for work in transplant infectious diseases.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

Collaboration with Professor Michael Nicholson's group for preclinical proof-of-concept studies in human donor kidneys. Professor Nicholson is Director of the NIHR Blood and Transplant Research Unit (BTRU) in Organ Donation and Transplantation and serves as Lead Coordinating Investigator for the UK Phase 1 trial.

3Professor Atul Humar
Strategic tierCoreTypeStrategic or Co-development Partner
Description

Principal Investigator of Phase 1 trial at UHN. Director at University of Toronto Transplant Institute (largest multi-organ transplantation centre in North America). Member of Synklino's Scientific Advisory Board since October 2020. Internationally recognized expert in transplant infectious diseases and CMV prevention.

synklino.com
4Professor John Sinclair
Strategic tierCoreTypeStrategic or Co-development Partner
Description

Member of Synklino's Scientific Advisory Board. Deputy Head of the Department of Medicine and Head of the Division of Infectious Diseases at Cambridge University. Expert on CMV life cycle, especially during latency.

synklino.com
Recent move7 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers8 records
TypeDirect peer
Description

Allogeneic T-cell therapy company with programs targeting viral infections in immunocompromised transplant patients, including CMV. Comparable in transplant-focused virology space and clinical-stage biotech profile, but uses cell therapy rather than a fusion protein.

TypeDirect peer
Description

Developed Viralym-M (now spun out as Kalaris Therapeutics), an allogeneic, multi-virus-specific T-cell therapy for transplant patients including those with refractory CMV. Closely comparable target patient population (transplant recipients with viral reactivation) and clinical-stage profile.

3Hookipa Pharma
TypeDirect peer
Description

Clinical-stage biotech developing HB-101, a CMV vaccine designed to prevent CMV reactivation in transplant recipients. Directly comparable to Synklino in target indication (post-transplant CMV), patient population, and clinical-stage biotech profile, though Hookipa uses a vaccine rather than an ex vivo immunotoxin approach.

TypeBroad incumbent
Description

Markets Prevymis (letermovir), the leading branded antiviral for CMV prophylaxis in adult CMV-seropositive transplant recipients. Represents the incumbent standard of care against which SYN002 will compete; broad incumbent with multiple therapeutic areas.

TypeBroad incumbent
Description

Markets Livtencity (maribavir), the first FDA-approved treatment for post-transplant CMV infection/disease refractory to existing antivirals. Directly competes with SYN002's indication and is a relevant potential strategic partner given its transplant franchise.

TypeBroad incumbent
Description

Developing mRNA-1647, an mRNA-based CMV vaccine currently in Phase 3 trials, the most advanced CMV vaccine program. Compares to Synklino in CMV prevention but as a much larger, late-stage company pursuing an in vivo vaccine approach rather than ex vivo biologic.

TypeEmerging player
Description

Developed VBI-1501, a CMV vaccine candidate that entered Phase 1 clinical evaluation. Comparable in targeting CMV with an immunotherapeutic approach, though VBI is broader and earlier-stage in the transplant CMV space.

TypeDirect peer
Description

Developing Triplex, a therapeutic CMV vaccine for use in stem cell and solid organ transplant recipients. Comparable in targeting CMV prevention in transplant recipients and clinical-stage biotech profile, though using a vaccine modality.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers1 record

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment2 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature3 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles7 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds3 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors5 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Synklino

Transplant Therapeuticssynklino.com

Synklino A/S is a Danish clinical-stage biotechnology company developing SYN002, a first-in-class ex vivo therapeutic fusion protein that eliminates cytomegalovirus from donor kidneys during machine perfusion, targeting latent and active CMV infection in kidney transplant recipients.

What Synklino does

Synklino A/S is a Danish clinical-stage biotechnology company founded in July 2017 as a spinout from the University of Copenhagen and the Technical University of Denmark, headquartered at Frederiksborggade 1, Copenhagen K. The company is developing a single lead product, SYN002, a first-in-class therapeutic fusion protein (immunotoxin) designed to eliminate cytomegalovirus (CMV) infection in donor kidneys prior to transplantation. SYN002 targets US28, a CMV-encoded membrane receptor exclusively expressed on virus-infected cells during both lytic and latent phases, and is administered ex vivo during normothermic machine perfusion, treating the donor organ directly without exposing the transplant recipient to systemic therapy.

SYN002 addresses a clear unmet need: approximately 30% of kidney transplant recipients receiving CMV-positive donor organs still experience CMV reactivation despite standard antiviral prophylaxis, leading to increased morbidity, mortality, organ rejection, and a roughly 50% rise in transplant-related costs. Preclinical data published in the American Journal of Transplantation demonstrated greater than 90% reduction in CMV reactivation from latency in treated human donor kidneys. Synklino retains broad intellectual property rights to SYN002 and its ex vivo use in organ perfusion, built on a decade of academic research from its founding universities. The company initiated first-in-human Phase 1 clinical trials in 2026, with the first patient dosed in May 2026 at the Ajmera Transplant Centre, University Health Network Toronto, under Principal Investigator Prof. Atul Humar.

The business model is licensing- and partnership-driven: Synklino intends to develop SYN002 through proof-of-concept and then partner with established pharmaceutical companies for late-stage development and global commercialization, generating revenue from upfront payments, development milestones, and royalties. The company has raised approximately EUR 43.8 million in total across a 2019 BioInnovation Institute grant (DKK 10m), a 2020 seed round (Eir Ventures and Vaekstfonden), a heavily oversubscribed 2021 financing round (DKK 106m/EUR 14m), and a 2022 Series A of EUR 29.8m led by PKA pension fund with Vaekstfonden and Eir Ventures. Ownership includes approximately 70 private shareholders alongside institutional investors. The company is privately held, pre-revenue, and has 11–50 employees.

Synklino firmographics

Firmographics
Name
Synklino
Legal name
Synklino A/S
Website
https://synklino.com
Company type
Private
Founded year
2017
Operating status
Operating
Headcount range
11–50 employees
Short description
Synklino A/S is a Danish clinical-stage biotechnology company developing SYN002, a first-in-class ex vivo therapeutic fusion protein that eliminates cytomegalovirus from donor kidneys during machine perfusion, targeting latent and active CMV infection in kidney transplant recipients.
Ownership category
akta.pro rank

Synklino industry classification

Industry
Product category
Transplant Therapeutics
NAICS
Research and Development in Biotechnology (except Nanobiotechnology) (541714)
SIC
In Vitro & In Vivo Diagnostic Substances (2835)
akta.pro industry
PRIMARYHLAAAAAD
Fusion Proteins & Fc-Engineered Biologics
Healthcare & Life Sciences/Biotechnology & Biologics/Therapeutic Biologics (mAbs, recombinant proteins, cytokines)
SECONDARYHLAAAAAJ
Engineered Protein Therapeutics (de novo/AI-designed proteins, novel scaffolds)
Healthcare & Life Sciences/Biotechnology & Biologics/Therapeutic Biologics (mAbs, recombinant proteins, cytokines)

Keywords

  • Cytomegalovirus therapeutics
  • Kidney transplant drugs
  • Ex vivo organ perfusion
  • Therapeutic fusion proteins
  • Antiviral immunotoxins

Where Synklino is headquartered

Location

Headquarters

HQ city
Copenhagen
HQ country
Denmark
HQ region
Europe

Offices1 record

Markets served

Synklino business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel, Operations, Marketing or Sales

Revenue model

  1. Pharmaceutical Licensing/Partnership: As a clinical-stage biotech, Synklino plans to develop SYN002 through proof-of-concept, after which they expect to partner with established pharma companies for late-stage development and commercialisation. Revenue will come from licensing deals, milestone payments, and royalties from commercial partners.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels4 records

Synklino product offering

Product offering

Core offering

Synklino develops SYN002, a first-in-class therapeutic fusion protein (immunotoxin) that targets the CMV-encoded US28 membrane receptor to eliminate both active and latent cytomegalovirus-infected cells in donor kidneys. The drug is administered ex vivo during normothermic machine perfusion of the donor organ prior to transplantation, treating the organ directly so the transplant recipient is not exposed to systemic antiviral therapy. The company is currently advancing SYN002 through a Phase 1 clinical trial at University Health Network Toronto.

Product overview

Synklino is a Danish clinical-stage biotechnology company developing a single lead product, SYN002, a first-in-class ex vivo therapy for preventing cytomegalovirus (CMV) reactivation in kidney transplant recipients. SYN002 is a therapeutic fusion protein administered during ex vivo organ perfusion (machine perfusion) prior to transplantation, enabling direct treatment of the donor organ without systemic exposure to the recipient. The company is currently advancing SYN002 through Phase 1 clinical development and has no additional commercial products or services.

Differentiator

Problem solved

Functional benefit

Products and services

  • SYN002 First-in-class therapeutic fusion protein (immunotoxin) that targets the CMV-encoded US28 membrane receptor on infected cells to eliminate both active (lytic) and latent cytomegalovirus from donor kidneys. Administered ex vivo during normothermic machine perfusion of the donor organ prior to transplantation, treating the donor organ directly so the transplant recipient is not exposed to systemic antiviral therapy. Intended for kidney transplant centers and their CMV-positive donor kidney recipients.

Quantifiable outcome

  • >90% reduction in CMV reactivation from latency in human kidneys treated ex vivo
  • +3 more outcomes

Companies that use Synklino

Customer profile

Named customers1 record

Segments2 records

Ideal customer profiles2 records

Synklino technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature3 records

Synklino partnerships and signals

Strategic signal

Partnerships

Four partnerships are on record, tiered core.

  • University Health Network (UHN), TorontocoreStrategic or Co-development PartnerAjmera Transplant Centre at UHN is conducting the Phase 1 clinical trial of SYN002. One of the world's leading transplant centers, performing more than 600 solid organ transplants each year. Study led by Professor Atul Humar, internationally recognized for work in transplant infectious diseases.
  • University of Cambridge / Addenbrooke's HospitalcoreStrategic or Co-development PartnerCollaboration with Professor Michael Nicholson's group for preclinical proof-of-concept studies in human donor kidneys. Professor Nicholson is Director of the NIHR Blood and Transplant Research Unit (BTRU) in Organ Donation and Transplantation and serves as Lead Coordinating Investigator for the UK Phase 1 trial.
  • Professor Atul HumarcoreStrategic or Co-development PartnerPrincipal Investigator of Phase 1 trial at UHN. Director at University of Toronto Transplant Institute (largest multi-organ transplantation centre in North America). Member of Synklino's Scientific Advisory Board since October 2020. Internationally recognized expert in transplant infectious diseases and CMV prevention.
  • Professor John SinclaircoreStrategic or Co-development PartnerMember of Synklino's Scientific Advisory Board. Deputy Head of the Department of Medicine and Head of the Division of Infectious Diseases at Cambridge University. Expert on CMV life cycle, especially during latency.

Scale indicators6 records

Recent moves7 records

Expansion highlights5 records

Synklino competitors and assessment

Company assessment

Direct peers

  • Atara Biotherapeutics: Allogeneic T-cell therapy company with programs targeting viral infections in immunocompromised transplant patients, including CMV. Comparable in transplant-focused virology space and clinical-stage biotech profile, but uses cell therapy rather than a fusion protein.
  • AlloVir: Developed Viralym-M (now spun out as Kalaris Therapeutics), an allogeneic, multi-virus-specific T-cell therapy for transplant patients including those with refractory CMV. Closely comparable target patient population (transplant recipients with viral reactivation) and clinical-stage profile.
  • Hookipa Pharma: Clinical-stage biotech developing HB-101, a CMV vaccine designed to prevent CMV reactivation in transplant recipients. Directly comparable to Synklino in target indication (post-transplant CMV), patient population, and clinical-stage biotech profile, though Hookipa uses a vaccine rather than an ex vivo immunotoxin approach.
  • Helocyte Pharmaceuticals: Developing Triplex, a therapeutic CMV vaccine for use in stem cell and solid organ transplant recipients. Comparable in targeting CMV prevention in transplant recipients and clinical-stage biotech profile, though using a vaccine modality.

Broad incumbents

  • Merck & Co. Markets Prevymis (letermovir), the leading branded antiviral for CMV prophylaxis in adult CMV-seropositive transplant recipients. Represents the incumbent standard of care against which SYN002 will compete; broad incumbent with multiple therapeutic areas.
  • Takeda Pharmaceutical: Markets Livtencity (maribavir), the first FDA-approved treatment for post-transplant CMV infection/disease refractory to existing antivirals. Directly competes with SYN002's indication and is a relevant potential strategic partner given its transplant franchise.
  • Moderna: Developing mRNA-1647, an mRNA-based CMV vaccine currently in Phase 3 trials, the most advanced CMV vaccine program. Compares to Synklino in CMV prevention but as a much larger, late-stage company pursuing an in vivo vaccine approach rather than ex vivo biologic.

Emerging players

  • VBI Vaccines: Developed VBI-1501, a CMV vaccine candidate that entered Phase 1 clinical evaluation. Comparable in targeting CMV with an immunotherapeutic approach, though VBI is broader and earlier-stage in the transplant CMV space.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

Synklino social profiles

Digital presence

Synklino financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Synklino leadership team

Management profile

Number of profiles

Profiles7 records

Synklino funding detail

Funding detail

Funding overview

Funding rounds3 records

Investors5 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Synklino M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Synklino

What does Synklino do?

Synklino develops SYN002, a first-in-class therapeutic fusion protein (immunotoxin) that targets the CMV-encoded US28 membrane receptor to eliminate both active and latent cytomegalovirus-infected cells in donor kidneys. The drug is administered ex vivo during normothermic machine perfusion of the donor organ prior to transplantation, treating the organ directly so the transplant recipient is not exposed to systemic antiviral therapy. The company is currently advancing SYN002 through a Phase 1 clinical trial at University Health Network Toronto.

Is Synklino a public or private company?

Synklino is a private company. It is classified as venture growth investor backed and is currently operating.

When was Synklino founded?

Synklino was founded in 2017. It employs 11 to 50 people.

Where is Synklino based?

Synklino is headquartered in Copenhagen, Denmark, in the Europe region.

How does Synklino make money?

One revenue line is on record: pharmaceutical Licensing/Partnership.

Who are Synklino's main competitors?

Direct peers on record are Atara Biotherapeutics, AlloVir, Hookipa Pharma and Helocyte Pharmaceuticals. Broad incumbents are Merck & Co., Takeda Pharmaceutical and Moderna. VBI Vaccines is listed as an emerging player.

Does Synklino have an API?

No public API is recorded for Synklino.

What industry is Synklino in?

Synklino's product category is Transplant Therapeutics. Its primary akta.pro industry code is HLAAAAAD, Fusion Proteins & Fc-Engineered Biologics, with a secondary code of HLAAAAAJ, Engineered Protein Therapeutics (de novo/AI-designed proteins, novel scaffolds). Its NAICS code is 541714 and its SIC code is 2835.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
BioSpaceSynklino announces first patient dosed in Phase 1 trial of SYN002 for CMV prevention in kidney transplantationSynklino announced the first patient has been dosed in a Phase 1 trial of SYN002 for CMV prevention in kidney transplant recipients. The study, led by Professor Atul Humar at UHN Toronto, will evaluate safety and exploratory efficacy over six months. Initial safety findings are expected in the second half of 2026, with final readout in 2027.PharmiWeb.comSynklino announces publication in American Journal of Transplantation highlighting proof-of-concept for SYN002 in eliminating CMV in human kidneysSynklino A/S, a Danish biotechnology company, has published preclinical data in the American Journal of Transplantation demonstrating that their SYN002 therapy achieved greater than 90% reduction in human cytomegalovirus reactivation from latency in human kidneys during normothermic machine perfusion. The proof-of-concept results follow regulatory clearance granted by both the UK MHRA and Health Canada for Phase 1 clinical trials, with the Canadian investigator-sponsored study at University Health Network in Toronto expected to begin enrolling patients in April 2026. The findings suggest SYN002 could fundamentally change CMV management in transplantation by intervening at the donor organ level before transplantation, addressing a significant unmet need as approximately 30% of patients receiving CMV-positive donor organs still experience reactivation despite standard prophylaxis.GlobeNewswireSynklino announces publication in American Journal of Transplantation highlighting proof-of-concept for SYN002 in eliminating CMV in human kidneysSynklino A/S, a Danish biotechnology company, announced publication of preclinical proof-of-concept data in the American Journal of Transplantation demonstrating that its drug candidate SYN002 achieved >90% reduction in human cytomegalovirus (CMV) reactivation from latency in human kidneys, compared with no reduction in control kidneys. The company has received regulatory clearance from both the UK MHRA and Health Canada for Phase 1 clinical trials of SYN002 in kidney transplantation, with the Canadian investigator-sponsored study led by Dr. Atul Humar at University Health Network (UHN) in Toronto expected to begin enrolling patients in April 2026.BioSpaceSynklino announces publication in American Journal of Transplantation highlighting proof-of-concept for SYN002 in eliminating CMV in human kidneysSynklino A/S, a Danish biotechnology company, announced the publication of preclinical data in the American Journal of Transplantation demonstrating that their drug candidate SYN002 achieved greater than 90% reduction in human cytomegalovirus reactivation from latency in treated human kidneys, compared with no reduction in control kidneys. The proof-of-concept data support the company's approach to eliminating CMV at the donor organ level before transplantation. Regulatory clearances have been granted by both the UK MHRA and Health Canada for Phase 1 clinical trials, with the Canadian study to be conducted by Dr. Atul Humar at University Health Network in Toronto, with first patient enrolment expected in April 2026.Business InsiderSynklino announces publication in American Journal of Transplantation highlighting proof-of-concept for SYN002 in eliminating CMV in human kidneysSynklino A/S published preclinical proof-of-concept data in the American Journal of Transplantation demonstrating that SYN002 achieved greater than 90% reduction in human cytomegalovirus reactivation from latency in treated human kidneys, compared with no reduction in controls. The company has received regulatory clearance from both the UK MHRA and Health Canada for Phase 1 clinical trials of SYN002 in kidney transplantation, with the Canadian investigator-sponsored study led by Dr. Atul Humar at UHN Toronto expected to enroll its first patient in April 2026.FinSMEsSynklino Closes EUR 29.8M Series A FundingSynklino, a Copenhagen-based biotech, raised EUR 29.8M in Series A funding. The company will use the funds to advance its CMV drug candidate SYN002 into Phase 1 clinical trials. CMV affects over 60% of adults and poses serious risks in transplant patients.SynklinoSynklino completes Series A raise of EUR 29.8 million to advance clinical trials of its drug candidate for the treatment of Cytomegalovirus (CMV)Danish biotech Synklino announced on 8 June 2022 that it has completed a Series A raise of EUR 29.8 million (USD 31.8 million) led by PKA pension fund, alongside The Danish Growth Fund and Eir Ventures. The company will advance its CMV candidate SYN002 into ex vivo and in vivo Phase 1 trials. Management aims to submit a clinical trial application in the first half of 2023.PR NewswireSynklino completes Series A raise of EUR 29.8 million to advance clinical trials of its drug candidate for the treatment of Cytomegalovirus (CMV)Synklino has completed a Series A fundraising round of EUR 29.8 million, led by PKA pension fund with participation from The Danish Growth Fund and Eir Ventures. The capital will be used to advance the clinical trials of its drug candidate SYN002 for the treatment of cytomegalovirus (CMV) into Phase 1 studies. This funding supports Synklino's goal to complete its clinical trial application in the first half of 2023.PR NewswireSynklino Strengthens Management Team with Key AppointmentsSynklino ApS, a Danish biotech company developing a treatment for cytomegalovirus infections in transplant patients, has appointed Tolga Hassan as Chief Financial Officer and Dr. Josefin-Beate Holz as Chief Medical Officer. The appointments follow a recent financing round led by Eir Ventures and Vaekstfonden, a Danish state-backed investment fund. The new executives bring over 25 years of experience each in biotech finance and pharmaceutical drug development, and will support the company's advancement of its lead program SYN002 toward clinical testing.SuperbCrewMeet Emerging Biotech Company Synklino: An Interview With CEO, Thomas N. KledalSynklino, an emerging biotech, developed a first-in-class anti-CMV drug candidate (SYN002) to eliminate cytomegalovirus infections in transplant patients. The company raised seed financing led by Eir Ventures and plans a Series A in spring 2021 to advance to clinical trials.